INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

Skaff Michael C bought VVOS

10% Owner · Vivos Therapeutics, Inc. · Vivos Therapeutics, Inc. — Series B Common Stock Warrant

Side
BUY
Value
$2.39M
Shares
1.78M
Price
$1.34
Executed
Mar 31, 2026
Disclosed
Apr 2, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 31 executedApr 2, 2026 disclosed

VVOS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
50/ 100 · NOTABLE
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+22 / 25

    $2.4M reported value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VVOS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    31
    LF
    Lindsay Mark F.Director
    VVOSVivos Therapeutics, Inc.
    Grant or award
    		A—
    12.0K sh
    		Sep 14, 2026Oct 26, 2026
    traded Sep 14, 2026
    		+42dSEC FORM 4

    Evidence

    31
    GE
    Green Ralph EliasDirector
    VVOSVivos Therapeutics, Inc.
    Grant or award
    		A—
    12.0K sh
    		Sep 14, 2026Oct 26, 2026
    traded Sep 14, 2026
    		+42dSEC FORM 4

    Evidence

    47
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$576K
    430.0K sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    50
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$1.40M
    1.04M sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    50
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$2.39M
    1.78M sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    43
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$414K
    308.8K sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002074003-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 31, 2026
    Published
    Apr 2, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Skaff Michael C
    Role
    10% Owner
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Vivos Therapeutics, Inc. — Series B Common Stock Warrant
    Ticker
    VVOS
    Shares
    1.78M
    Price per share
    $1.34
    Value
    $2,390,000
    Execution date (reported)
    Mar 31, 2026
    Owned after transaction
    1.78M shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 1.78M
    • Price: $1.34

    = $2,390,000

    What this establishes

    Skaff Michael C filed this Form 4 reporting a open-market purchase of VVOS on Mar 31, 2026. It became public on Apr 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    10% Owner
    Skaff Michael Ccik:0002074003
    Issuer
    Vivos Therapeutics, Inc.cik:0001716166

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.